Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy - 15/02/21
Funding sources: None. |
|
Conflicts of interest: Dr Hanna reports grant/research support from Exicure, GSK, Regeneron, Sanofi Genzyme, and Kartos, and consulting/advisory for Regeneron, Sanofi Genzyme, Maverick, Merck, and Kura. Drs DeCaprio and Thakuria have served as consultants to Merck & Co, Inc and EMD Serono, Inc. Dr DeCaprio has also received research funding from Constellation Pharmaceuticals, Inc. Dr Catalano reports receiving personal fees from Eli Lilly (Data and Safety Monitoring Board). Dr Schoenfeld has served as a consultant for and received travel fees from Debiopharm, Bristol-Meyers Squibb, Nanobiotix, Tilos, AstraZeneca, LEK, and Catenion, and has also received research support from Merck, BMS, and Regeneron. Dr Tishler has received personal fees from Regeneron (advisory board) and PSI/Oragenics (Data and Safety Monitoring Board). Dr Silk has served as a consultant to Bristol-Meyers Squibb, Merck & Co, Inc, and EMD Serono, Inc. Drs Chipidza, Margalit, and Yoon have no conflicts of interest to disclose. |
|
IRB approval status: Reviewed and approved by the Dana Farber Cancer Institute Institutional Review Board committee under protocol #2019P001578. |
|
Reprints not available from the authors. |
Vol 84 - N° 3
P. 875-877 - mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?